Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)

Market Cap	7.19B +109.2%
Revenue (ttm)	1.53B -10.7%
Net Income	-1.42B
EPS	-2.16
Shares Out	661.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,388,590
Average Volume	19,098,701
Open	10.51
Previous Close	10.64
Day's Range	10.51 - 10.97
52-Week Range	7.21 - 12.79
Beta	0.54
RSI	60.55
Earnings Date	Apr 29, 2026

About Xiangxue Pharmaceutical

Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet sarsae, juice soda, soymilk, coconut juice, and fruit enzyme; and antiviral oral liquids under the Xiangxue brand name. It also provides medical devices...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 2,769
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300147

Financial Performance

In 2025, Xiangxue Pharmaceutical's revenue was 1.60 billion, a decrease of -14.16% compared to the previous year's 1.86 billion. Losses were -1.39 billion, 62.2% more than in 2024.